Synthetic lethality: the road to novel therapies for breast cancer.
View/ Open
Date
2016-10-01ICR Author
Author
Dhillon, KK
Bajrami, I
Taniguchi, T
Lord, CJ
Type
Journal Article
Metadata
Show full item recordAbstract
When the BRCA1 and BRCA2 tumour suppressor genes were identified in the early 1990s, the immediate implications of mapping, cloning and delineating the sequence of these genes were that individuals in families with a BRCA gene mutation could be tested for the presence of a mutation and their risk of developing cancer could be predicted. Over time though, the discovery of BRCA1 and BRCA2 has had a much greater influence than many might have imagined. In this review, we discuss how the discovery of BRCA1 and BRCA2 has not only provided an understanding of the molecular processes that drive tumourigenesis but also reignited an interest in therapeutically exploiting loss-of-function alterations in tumour suppressor genes.
Collections
Subject
Animals
Humans
Breast Neoplasms
Genetic Predisposition to Disease
Therapies, Investigational
Genes, Lethal
Female
Molecular Targeted Therapy
Synthetic Lethal Mutations
Research team
Gene Function
Language
eng
Date accepted
2016-08-15
License start date
2016-10
Citation
Endocrine-related cancer, 2016, 23 (10), pp. T39 - T55
Publisher
BIOSCIENTIFICA LTD